An epigenome editing system generally includes three exogenous coding regions. The first exogenous coding region encodes a first polypeptide that includes an epigenetic editing domain and a domain that, in the presence of an inducer, forms a complex with a second polypeptide. The second exogenous coding region encodes the second polypeptide, which includes a dCas9 domain and a domain that, in the presence of the inducer, forms a complex with the first polypeptide. The third exogenous coding region encodes an sgRNA sequence that targets the dCas9 domain to a genomic locus.

Disclosed herein are compositions and methods for programming immune cell function though targeted gene regulation.

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.

Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.

Disclosed herein are CRISPR/Cas9-based gene activation systems that include a fusion protein of a Cas9 protein and a protein having histone acetyltransferase activity, and methods of using said systems.

Disclosed herein are CRISPR/Cas9-based gene activation systems that include a fusion protein of a Cas9 protein and a protein having histone acetyltransferase activity, and methods of using said systems.

Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenotnic engineering, genome targeting, and genome editing.

Disclosed herein are CRISPR/Cas9-based gene activation systems that include a fusion protein of a Cas9 protein and a protein having histone acetyltransferase activity, and methods of using said systems.

Squalene Hopene Cyclase (SHC) enzymes and variants thereof and their uses for making ()-Ambrox from homofarnesol and Ambra oxide from bishomofarnesol and the like.